2023

  1. ICD-10-CM Codes
    2. ›
  2. C00-D49
    3. ›
  3. C81-C96
    4. ›
  4. C90-
    5. ›
  5. 2023 ICD-10-CM Diagnosis Code C90

2023 ICD-10-CM Diagnosis Code C90

New Call-to-action

Multiple myeloma and malignant plasma cell neoplasms

    2016 2017 2018 2019 2020 2021 2022 2023 Non-Billable/Non-Specific Code
  • C90 should not be used for reimbursement purposes as there are multiple codes below it that contain a greater level of detail.
  • The 2023 edition of ICD-10-CM C90 became effective on October 1, 2022.
  • This is the American ICD-10-CM version of C90 - other international versions of ICD-10 C90 may differ.
Type 1 Excludes
Type 1 Excludes Help
A type 1 excludes note is a pure excludes. It means "not coded here". A type 1 excludes note indicates that the code excluded should never be used at the same time as C90. A type 1 excludes note is for used for when two conditions cannot occur together, such as a congenital form versus an acquired form of the same condition.
  • personal history of other malignant neoplasms of lymphoid, hematopoietic and related tissues (
    ICD-10-CM Diagnosis Code Z85.79

    Personal history of other malignant neoplasms of lymphoid, hematopoietic and related tissues

      2016 2017 2018 2019 2020 2021 2022 2023 Billable/Specific Code POA Exempt
    Applicable To
    Type 1 Excludes
    • multiple myeloma in remission (C90.01)
    • plasma cell leukemia in remission (C90.11)
    • plasmacytoma in remission (C90.21)
    Z85.79
    )
The following code(s) above C90 contain annotation back-references
Annotation Back-References
In this context, annotation back-references refer to codes that contain:
  • Applicable To annotations, or
  • Code Also annotations, or
  • Code First annotations, or
  • Excludes1 annotations, or
  • Excludes2 annotations, or
  • Includes annotations, or
  • Note annotations, or
  • Use Additional annotations
that may be applicable to C90:
  • C00-D49
    2023 ICD-10-CM Range C00-D49

    Neoplasms

    Note
    • Functional activity
    • All neoplasms are classified in this chapter, whether they are functionally active or not. An additional code from Chapter 4 may be used, to identify functional activity associated with any neoplasm.
    • Morphology [Histology]
    • Chapter 2 classifies neoplasms primarily by site (topography), with broad groupings for behavior, malignant, in situ, benign, etc. The Table of Neoplasms should be used to identify the correct topography code. In a few cases, such as for malignant melanoma and certain neuroendocrine tumors, the morphology (histologic type) is included in the category and codes.
    • Primary malignant neoplasms overlapping site boundaries
    • A primary malignant neoplasm that overlaps two or more contiguous (next to each other) sites should be classified to the subcategory/code .8 ('overlapping lesion'), unless the combination is specifically indexed elsewhere. For multiple neoplasms of the same site that are not contiguous, such as tumors in different quadrants of the same breast, codes for each site should be assigned.
    • Malignant neoplasm of ectopic tissue
    • Malignant neoplasms of ectopic tissue are to be coded to the site mentioned, e.g., ectopic pancreatic malignant neoplasms are coded to pancreas, unspecified (C25.9).
    Neoplasms
  • C81-C96
    2023 ICD-10-CM Range C81-C96

    Malignant neoplasms of lymphoid, hematopoietic and related tissue

    Type 2 Excludes
    • Kaposi's sarcoma of lymph nodes (C46.3)
    • secondary and unspecified neoplasm of lymph nodes (C77.-)
    • secondary neoplasm of bone marrow (C79.52)
    • secondary neoplasm of spleen (C78.89)
    Malignant neoplasms of lymphoid, hematopoietic and related tissue
Code History
  • 2016 (effective 10/1/2015): New code (first year of non-draft ICD-10-CM)
  • 2017 (effective 10/1/2016): No change
  • 2018 (effective 10/1/2017): No change
  • 2019 (effective 10/1/2018): No change
  • 2020 (effective 10/1/2019): No change
  • 2021 (effective 10/1/2020): No change
  • 2022 (effective 10/1/2021): No change
  • 2023 (effective 10/1/2022): No change
ICD-10-CM Codes Adjacent To C90
C86.4 Blastic NK-cell lymphoma
C86.5 Angioimmunoblastic T-cell lymphoma
C86.6 Primary cutaneous CD30-positive T-cell proliferations
C88 Malignant immunoproliferative diseases and certain other B-cell lymphomas
C88.0 Waldenström macroglobulinemia
C88.2 Heavy chain disease
C88.3 Immunoproliferative small intestinal disease
C88.4 Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue [MALT-lymphoma]
C88.8 Other malignant immunoproliferative diseases
C88.9 Malignant immunoproliferative disease, unspecified
C90 Multiple myeloma and malignant plasma cell neoplasms
C90.0 Multiple myeloma
C90.00 …… not having achieved remission
C90.01 …… in remission
C90.02 …… in relapse
C90.1 Plasma cell leukemia
C90.10 …… not having achieved remission
C90.11 …… in remission
C90.12 …… in relapse
C90.2 Extramedullary plasmacytoma
C90.20 …… not having achieved remission

Reimbursement claims with a date of service on or after October 1, 2015 require the use of ICD-10-CM codes.

Advertise with Us | License ICD10 Data

Copyright © | ICD10data.com